Publication Cover
Archives of Physiology and Biochemistry
The Journal of Metabolic Diseases
Volume 128, 2022 - Issue 6
233
Views
6
CrossRef citations to date
0
Altmetric
Review Article

Glibenclamide as a neuroprotective antidementia drug

ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon
Pages 1693-1696 | Received 28 May 2020, Accepted 24 Jun 2020, Published online: 11 Jul 2020
 

Abstract

In the view of progressively aging human population and increased occurrence of dysmetabolic disorders, such as diabetes mellitus, cognitive impairment becomes a major threat to the national health. To date, the molecular mechanisms of cognitive dysfunction are partially described for diabetes and diseases of different nature, such as Alzheimer disease or Parkinson disease. The emergence of data pointing towards pleotropic effects of hypoglycaemic medicines indicates involvement of their targets in pathogenesis of cognitive impairment. We are aiming here to review available data on the most widely used hypoglycaemic drug, glibenclamide and find possible relationship of its targets to the pathogenesis of cognitive impairment.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The reported study was funded by RFBR, project number 20–015-00168.

Notes on contributors

Alexander Zubov

Alexander S. Zubov is a PhD student (Physiology) of the Laboratory of Neurochemistry, I.P. Pavlov Department of Physiology, Institute of Experimental Medicine, St. Petersburg, Russia.

Zamira Muruzheva

Zamira M. Muruzheva, PhD (Medicine), is a Senior Researcher at the Laboratory of Neurobiology of Integrative Brain Functions, I.P. Pavlov Department of Physiology, Institute of Experimental Medicine, Saint Petersburg, Russia.

Maria Tikhomirova

Maria S. Tikhomirova is a PhD student at the Institute of Molecular Life Science, University of Zurich, Zurich; Researcher at the Laboratory of Neurobiology of Integrative Brain Functions, I.P. Pavlov Department of Physiology, Institute of Experimental Medicine, Saint Petersburg, Russia

Marina Karpenko

Marina N. Karpenko, MD, PhD (Biology), is the Head of the Laboratory of Neurochemistry, I.P. Pavlov Department of Physiology, Institute of Experimental Medicine, Saint Petersburg, Russia.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.